SeaStar Medical's Quellimmune Therapy: Pediatric AKI Success & Adult Market Push

SeaStar Medicals Q1 2026 earnings show robust growth in Quellimmune therapy for pediatric AKI, with net revenue surging 69% to $495,000. They added 7 new hospitals, targeting 15 customers and $2 million in full-year sales. The company is also making strides in the adult AKI market, with 198 out of 339 patients enrolled in the NEUTRALIZE-AKI trial. The medical community is excited about their selective cytokine device tech, with plans to submit SAVE registry safety data to the FDA soon. Despite a net loss of $3.5 million, SeaStar Medical is optimistic about FDA talks for modular approvals and breakthrough paths, potentially revolutionizing adult AKI treatment. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/8db2e203623c9b25